Company: DHR
Filing Date: 2025-10-21
Form Type: 10-Q
Source: 0000313616-25-000182
Chunk: 18

Company: DANAHER CORP /DE/
Filing Date: 2025-10-21
Form: 10-Q
Item: Item 1
Chunk 18
---
 2025, the Company divested a product line for a cash purchase price of $9 million and recognized a pretax gain on sale of $9 million ($7 million after-tax).  The divested product line generated revenues of approximately $50 million in the Diagnostics segment in 2024.  The divestiture of this product line did not represent a strategic shift with a major effect on the Company’s operations and financial results and therefore is not reported as a discontinued operation.

NOTE 8.  GOODWILL AND OTHER INTANGIBLE ASSETS 

The following is a rollforward of the Company’s goodwill ($ in millions):Balance, December 31, 2024$40,497 Adjustments due to finalization of purchase price allocations9 Foreign currency translation and other2,442 Balance, September 26, 2025$42,948 The carrying value of goodwill by segment is summarized as follows ($ in millions):September 26, 2025December 31, 2024Biotechnology$23,145 $21,437 Life Sciences12,837 12,305 Diagnostics6,966 6,755 Total$42,948 $40,497 

14

The Company reviews identified intangible assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable.  During the third quarter of 2024, the Company concluded that it had an impairment indicator for an indefinite-lived trade name within the genomics consumable business included in the Life Sciences segment, primarily as a result of softness in the genomics market, including but not limited to the discontinuation of certain drug development programs announced in the third quarter of 2024, weaker demand at some of the business’s larger customers as well as reduced demand due to the reprioritization of drug development programs at other customers.  The Company engaged a third-party valuation specialist to assist in the valuation of the trade name using a relief from royalty method of valuation.  The significant assumptions in the relief from royalty method included, but were not limited to, revenue, revenue growth rates, planned use of the trade name, royalty rates and discount rates.  The Company recorded a noncash impairment charge of $222 million pretax ($169 million after-tax) related to the trade name for the three and nine-month periods ended September 27, 2024, which is included in selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of E